Reference
Thompson M. Direct Healthcare Professional Communication on the importance of establishing wild-type RAS (exons 2,3 and 4 of KRAS and NRAS) status before treatment with Erbitux (cetuximab). Internet Document : [4 pages], 30 Dec 2014. Available from: URL: http://www.imb.ie/images/uploaded/documents/Erbitux%20DHPC%20Dec%202013%20Republic%20of%20Ireland%20final.pdf
Rights and permissions
About this article
Cite this article
Cetuximab use in mCRC restricted to wild-type RAS only. Reactions Weekly 1486, 2 (2014). https://doi.org/10.1007/s40278-014-8485-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-014-8485-0